The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Farnesoid X Receptor Regulation of the NLRP3 Inflammasome Underlies Cholestasis-Associated Sepsis
Open accessAbstract
SUMMARY Cholestasis is a common complication of sepsis, and the increased plasma levels of bile acids are predictive of sepsis-associated mortality. However, the exact mechanism by which cholestasis aggravates sepsis development remains elusive. Here, we show that bile acids are danger-associated molecular patterns (DAMPs) that can activate both signal 1 and 2 of the NLRP3 inflammasome in inflammatory macrophages. Mechanistically, bile acids induce a prolonged calcium influx and activate the NLRP3 inflammasome synergistically with ATP. Experimental cholestasis sensitizes, while cholestyramine, a bile acid sequestrant, protects mice from LPS-induced sepsis. FXR negatively regulates the NLRP3 inflammasome via physical interaction with NLRP3 and caspase 1. Fxr-null mice are more sensitive, while FXR-overexpressing mice are more resistant, to endoxemia shock. These findings suggest that bile acids and FXR play pivotal roles in sepsis via controlling the NLRP3 inflammasome, and that targeting FXR may represent a therapeutic strategy for cholestasis-associated sepsis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Moon, J.-S., Nakahira, K., Chung, K.-P., DeNicola, G. M., Koo, M. J., Pabón, M. A., Rooney, K. T., Yoon, J.-H., Ryter, S. W., Stout-Delgado, H., et al. (2016) · Nature Medicine · doi:10.1038/nm.4153 · Cited by 291
RetractedUCP2-induced fatty acid synthase promotes NLRP3 inflammasome activation during sepsis
Moon, J.-S., Lee, S., Park, M.-A., Siempos, I. I., Haslip, M., Lee, P. J., Yun, M., Kim, C. K., Howrylak, J., Ryter, S. W., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78253 · Cited by 238
RetractedMartinon, F., Burns, K., & Tschopp, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00599-3 · Cited by 6,066 · cited 2×
“Inflammasomes are a class of cytoplasmic protein complexes sensing endogenous or exogenous pathogen-associated molecular patterns (PAMPs) or danger-associated molecular patterns (DAMPs) that induce inflammatory responses by governing the cleavage of proinflammatory cytokines, including pro-IL1b and pro-IL18 (Mariathas…”
BackgroundGout-associated uric acid crystals activate the NALP3 inflammasome
Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., & Tschopp, J. (2006) · Nature · doi:10.1038/nature04516 · Cited by 5,326
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026 · cited 1×
“…diseases (Dinarello, 2009; Youm et al., 2015), and metabolic 856 Cell Metabolism 25, 856–867, April 4, 2017 ª 2017 Elsevier Inc. diseases, including diabetes (Jourdan et al., 2013), obesity (Vandanmagsar et al., 2011), gout (Martinon et al., 2006), and atherosclerosis (Duewell et al., 2010).”
BackgroundThe NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance
Vandanmagsar, B., Youm, Y.-H., Ravussin, A., Galgani, J. E., Stadler, K., Mynatt, R. L., Ravussin, E., Stephens, J. M., & Dixit, V. D. (2011) · Nature Medicine · doi:10.1038/nm.2279 · Cited by 2,655
Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis
Shimada, K., Crother, T. R., Karlin, J., Dagvadorj, J., Chiba, N., Chen, S., Ramanujan, V. K., Wolf, A. J., Vergnes, L., Ojcius, D. M., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.01.009 · Cited by 2,282
The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease
Youm, Y.-H., Nguyen, K. Y., Grant, R. W., Goldberg, E. L., Bodogai, M., Kim, D., D'Agostino, D., Planavsky, N., Lupfer, C., Kanneganti, T. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3804 · Cited by 2,172
Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf
Mariathasan, S., Newton, K., Monack, D. M., Vucic, D., French, D. M., Lee, W. P., Roose-Girma, M., Erickson, S., & Dixit, V. M. (2004) · Nature · doi:10.1038/nature02664 · Cited by 1,839
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Self-citation
Cited by
Gut-Microbiota-Derived Metabolites Maintain Gut and Systemic Immune Homeostasis
Wang, J., Zhu, N., Su, X., Gao, Y., & Yang, R. (2023) · Cells · doi:10.3390/cells12050793 · Cited by 588
Bile Acids Activated Receptors Regulate Innate Immunity
Fiorucci, S., Biagioli, M., Zampella, A., & Distrutti, E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01853 · Cited by 562
Fleishman, J. S., & Kumar, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01811-6 · Cited by 544
Pharmacological targeting of endoplasmic reticulum stress in disease
Marciniak, S. J., Chambers, J. E., & Ron, D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00320-3 · Cited by 520
Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology
Fuchs, C. D., & Trauner, M. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00566-7 · Cited by 490
Cleavage of GSDME by caspase-3 determines lobaplatin-induced pyroptosis in colon cancer cells
Yu, J., Li, S., Qi, J., Chen, Z., Wu, Y., Guo, J., Wang, K., Sun, X., & Zheng, J. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1441-4 · Cited by 483
Molecular physiology of bile acid signaling in health, disease, and aging
Perino, A., Demagny, H., Velazquez-Villegas, L., & Schoonjans, K. (2021) · Physiological Reviews · doi:10.1152/physrev.00049.2019 · Cited by 481
Gut microbiome, liver immunology, and liver diseases
Wang, R., Tang, R., Li, B., Ma, X., Schnabl, B., & Tilg, H. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00592-6 · Cited by 466
Gut–liver axis: barriers and functional circuits
Pabst, O., Hornef, M. W., Schaap, F. G., Cerovic, V., Clavel, T., & Bruns, T. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00771-6 · Cited by 436
Bile acids as modulators of gut microbiota composition and function
Larabi, A. B., Masson, H. L. P., & Bäumler, A. J. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2172671 · Cited by 401
Cong, J., Liu, P., Han, Z., Ying, W., Li, C., Yang, Y., Wang, S., Yang, J., Cao, F., Shen, J., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.02.014 · Cited by 303
Inflammasomes in the gastrointestinal tract: infection, cancer and gut microbiota homeostasis
Man, S. M. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0054-1 · Cited by 302
NLRP3: A promising therapeutic target for autoimmune diseases
Shen, H.-H., Yang, Y.-X., Meng, X., Luo, X.-Y., Li, X.-M., Shuai, Z.-W., Ye, D.-Q., & Pan, H.-F. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.01.020 · Cited by 271
Blood-Brain Barrier Disruption by Lipopolysaccharide and Sepsis-Associated Encephalopathy
Peng, X., Luo, Z., He, S., Zhang, L., & Li, Y. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.768108 · Cited by 267
Bile acids and their receptors in metabolic disorders
Fiorucci, S., Distrutti, E., Carino, A., Zampella, A., & Biagioli, M. (2021) · Progress in Lipid Research · doi:10.1016/j.plipres.2021.101094 · Cited by 258
SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis
Zhou, J., Cui, S., He, Q., Guo, Y., Pan, X., Zhang, P., Huang, N., Ge, C., Wang, G., Gonzalez, F. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14138-6 · Cited by 154
Self-citationEDP-305 in patients with NASH: a phase II double-blind placebo-controlled dose-ranging study
Ratziu, V., Rinella, M. E., Neuschwander-Tetri, B. A., Lawitz, E., Denham, D., Kayali, Z., Sheikh, A., Kowdley, K. V., Desta, T., Elkhashab, M., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.018 · Cited by 123
Bile acids activated receptors in inflammatory bowel disease
Biagioli, M., Marchianò, S., Carino, A., Di Giorgio, C., Santucci, L., Distrutti, E., & Fiorucci, S. (2021) · Cells · doi:10.3390/cells10061281 · Cited by 103
“Like FXR, GPBAR1 also exerts a counter-regulatory effects on the activation of the NLPR3 inflammasome [50,53].”
BackgroundCombined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis
Zhou, J., Huang, N., Guo, Y., Cui, S., Ge, C., He, Q., Pan, X., Wang, G., Wang, H., & Hao, H. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.11.004 · Cited by 99
Self-citation(2025) · doi:10.1038/s41423-025-01313-7 · Cited by 97
Noncanonical farnesoid X receptor signaling inhibits apoptosis and impedes liver fibrosis
Wang, H., Ge, C., Zhou, J., Guo, Y., Cui, S., Huang, N., Yan, T., Cao, L., Che, Y., Zheng, Q., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.10.028 · Cited by 55
Self-citationShan, H.-M., Zang, M., Zhang, Q., Shi, R.-B., Shi, X.-J., Mamtilahun, M., Liu, C., Luo, L.-L., Tian, X., Zhang, Z., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01838-w · Cited by 53
NLRP3 inflammasome activation mechanism and its role in autoimmune liver disease
Guan, Y., Gu, Y., Li, H., Liang, B., Han, C., Zhang, Y., Liu, Q., Wei, W., & Ma, Y. (2022) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2022137 · Cited by 48
Sun, X., Chen, Z., Yu, L., Zeng, W., Sun, B., Fan, H., & Bai, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1205323 · Cited by 33
“The FXR agonism exert anti-inflammatory effects by inhibiting inflammatory signaling pathways, including the NF-κB signaling pathway and the NLRP3 inflammasome signaling pathway (Gadaleta et al., 2011; Hao et al., 2017).”
BackgroundQian, S., Su, Z., Lin, J., Hou, Q., Wang, X., Li, Y., Wang, J., Huang, C., Wang, Z., Cubero, F. J., et al. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02224-w · Cited by 24
Odoribacter laneus protects intestinal barrier by bile acid-FXR axis in acute pancreatitis
Gu, R., Li, J., Qi, J., Sun, R., Wu, H., & Jin, B. (2026) · AMB Express · doi:10.1186/s13568-026-02071-z · Cited by 2
“Bacteroides dorei alleviates the intestinal barrier in colitis mice via regulating BAs metabolism and the FXR-NLRP3 signaling pathway (Hao et al. 2017).”
Metadata
- Authors
- Hao, H., Cao, L., Jiang, C., Che, Y., Zhang, S., Takahashi, S., Wang, G., & Gonzalez, F. J.
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2017-04
- Volume
- 25
- Issue
- 4
- Pages
- 856-867.e5
- ISSN
- 1550-4131 (ISSN-L)
- OpenAlex
- W2605001341
- Cited by
- 469
- References
- 44
- FWCI
- 9.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.